Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review

Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relieve failur...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hong-Bo, Yang, Zi-Han, Guo, Qing-Qu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611916/
https://www.ncbi.nlm.nih.gov/pubmed/34819086
http://dx.doi.org/10.1186/s12964-021-00789-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611916/
https://www.ncbi.nlm.nih.gov/pubmed/34819086
http://dx.doi.org/10.1186/s12964-021-00789-w

Ejemplares similares